Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting a consolidated net loss of ₹276.34 crore for the year.
Noted waiver of fines by BSE for past non-compliance with SEBI LODR Regulation 19 and advised management to ensure stricter regulatory compliance.
Approved convening the 37th Annual General Meeting on August 25, 2026, through video conferencing/audio-visual means.
Provided updates on clinical pipeline including Phase 3 enrollment progress for SUVN-502 and initiation of Phase 3 study for SUVN-G3031.